Fabhalta (iptacopan) is an oral, Factor B inhibitor of the alternative complement pathway 6-7.

RedChip Companies will air interviews with Calidi Biotherapeutics, Inc. (NYSE American:CLDI) and OS Therapies Inc. (NYSE American:OSTX) on the RedChip Small Stocks, Big Money™ show, a sponsored ...

Thought LeadersAoife Hayes, Kevin O'Regan & Julie ScanlonClinical Trials Assitant, Operations Manager & Quality Assurance ...

The stress axis that has been most extensively studied in relation to stress is unquestionably the hypothalamic pituitary ...

Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) publishes its year-end report for the period January - December 2024. The report is available on ...

What does it mean for a computer to think like a doctor? This question has vexed physicians working on clinical reasoning artificial intelligence (AI) for more than 70 years. The first generation of ...

Q4 2024 Earnings Conference Call February 27, 2025 4:30 PM ETCompany ParticipantsYvonne Briggs - Alliance Advisors IRDr.

Clinical laboratories still face uncertainty and the difficult decision of whether to start the work needed to comply with ...

Phase 3 topline data from azetukalner FOS epilepsy program planned for H2 2025 in support of NDA filing and potential commercial launch– First ...

ACCESS and ACCESS II studies fully enrolled; topline data from both studies anticipated by year-end 2025Oral small ...

Financial Guidance: Celldex believes that the cash, cash equivalents and marketable securities at December 31, 2024 are sufficient to meet estimated working capital requirements and fund current ...

A higher comorbidity burden was linked to an increased rate of adverse events as well as early discontinuation among patients ...